Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelarabine in Refractory/Relapsed T-ALL or T-Lymphoblastic Lymphoma
NCT00684619Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Jun 2003
- Primary completion
- Dec 2008
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelarabine in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by Goethe University Frankfurt. Primary endpoint: Tolerability and Efficacy of Compound GW506U78. Started Jun 2003; status: completed.
02
Drugs
nelarabine
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT00684619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684619.